Tarsons Products Ltd
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]
- Market Cap ₹ 1,046 Cr.
- Current Price ₹ 197
- High / Low ₹ 458 / 164
- Stock P/E 49.2
- Book Value ₹ 118
- Dividend Yield 0.00 %
- ROCE 6.91 %
- ROE 4.75 %
- Face Value ₹ 2.00
Pros
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of BSE Healthcare BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 229 | 301 | 296 | 392 | 414 | |
| 125 | 148 | 196 | 282 | 294 | |
| Operating Profit | 103 | 153 | 100 | 111 | 121 |
| OPM % | 45% | 51% | 34% | 28% | 29% |
| 5 | 8 | 11 | 16 | 20 | |
| Interest | 3 | 4 | 10 | 20 | 22 |
| Depreciation | 14 | 22 | 40 | 62 | 87 |
| Profit before tax | 92 | 135 | 61 | 45 | 32 |
| Tax % | 25% | 25% | 30% | 34% | |
| 69 | 101 | 43 | 30 | 20 | |
| EPS in Rs | 3,583.25 | 18.92 | 8.01 | 5.60 | 3.82 |
| Dividend Payout % | 0% | 0% | 25% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -34% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -29% |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.19 | 11 | 11 | 11 | 11 |
| Reserves | 244 | 479 | 602 | 620 | 616 |
| 34 | 22 | 269 | 339 | 396 | |
| 18 | 33 | 90 | 111 | 141 | |
| Total Liabilities | 296 | 544 | 972 | 1,080 | 1,164 |
| 120 | 189 | 336 | 536 | 583 | |
| CWIP | 22 | 32 | 267 | 233 | 251 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 153 | 323 | 369 | 311 | 330 | |
| Total Assets | 296 | 544 | 972 | 1,080 | 1,164 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 68 | 83 | 103 | 114 | |
| -64 | -138 | -285 | -145 | |
| -27 | 130 | 136 | 39 | |
| Net Cash Flow | -23 | 75 | -47 | 8 |
| Free Cash Flow | 6 | -48 | -81 | -37 |
| CFO/OP | 89% | 77% | 121% | 117% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 75 | 79 | 96 | 74 |
| Inventory Days | 277 | 478 | 572 | 355 |
| Days Payable | 35 | 75 | 65 | 44 |
| Cash Conversion Cycle | 317 | 482 | 602 | 385 |
| Working Capital Days | 108 | 150 | -1 | 38 |
| ROCE % | 35% | 7% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Days Inventory Outstanding Days |
|
||||||
| Average Collection Period Days |
|||||||
| Number of Domestic Distributors Count ・Standalone data |
|||||||
| Number of International Distributors Count ・Standalone data |
|||||||
| Number of Manufacturing Machines Count ・Standalone data |
|||||||
| Number of Manufacturing Moulds Count ・Standalone data |
|||||||
| Number of SKUs Count ・Standalone data |
|||||||
| Domestic Labware Market Share % ・Standalone data |
|||||||
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
1d - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026
-
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
1d - Tarsons completed EUR 300,000 equity infusion in Singapore subsidiary for loan repayment and expenses.
-
Appointment Of Mr. Vinesh Mohan Kriplani
8 Apr - Shareholders approved Vinesh Mohan Kriplani’s appointment as independent director for five years from February 6, 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 8 Apr
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 8 Apr
Annual reports
Concalls
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptAI SummaryPPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Feb 2024TranscriptAI SummaryPPT
-
Dec 2023TranscriptPPTREC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
India’s Leading Labware Company[1]
One of the leading Indian labware company engaged in designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop
equipment & instruments)